NYSEMKT: AIMAim Immunotech Inc Stock
$0.40-0.02 (-4.76%)
Updated Mar 27, 2023
AIM Price
$0.40
Fair Value Price
N/A
Market Cap
$19.23M
52 Week Low
$0.29
52 Week High
$1.38
P/E
-0.93x
P/B
0.45x
P/S
208.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$134.00k
Earnings
-$20.90M
Gross Margin
-140.3%
Operating Margin
-15,598.51%
Profit Margin
-15,598.5%
Debt to Equity
0.08
Operating Cash Flow
-$16M
Beta
-0.34
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AIM Overview
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The company is headquartered in Ocala, Florida and currently employs 31 full-time employees. The firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The firm's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The firm's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIM is good value based on its book value relative to its share price (0.45x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
AIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIM due diligence checks available for Premium users.
Be the first to know about important AIM news, forecast changes, insider trades & much more!
Valuation
AIM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.93x
Industry
18.55x
Market
21.44x
AIM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.45x
Industry
4.86x
AIM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIM's financial health
Profit margin
Revenue
$21.0k
Net Income
-$6.4M
Profit Margin
-30,404.8%
AIM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$46.3M
Liabilities
$3.6M
Debt to equity
0.08
AIM's short-term assets ($41.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIM's short-term assets ($41.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
$250.0k
Financing
$25.0k
AIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIM vs Biotech Stocks
Aim Immunotech Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.